Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD: Protocol for Randomized Controlled Trial

NCT07708337 is registered in ClinicalTrials.gov with Capital Development Authority (CDA) as lead sponsor.

NCT NCT07708337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD: Protocol for Randomized Controlled Trial
Lead sponsor
Capital Development Authority (CDA)
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 26, 2026
Completion date
February 28, 2027
Enrollment
560 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute exacerbation of copd, copd